{"id":659986,"date":"2026-10-06T13:10:50","date_gmt":"2026-10-06T11:10:50","guid":{"rendered":"https:\/\/preprod.aivancity.ai\/blog\/alphagenome-atlas-what-mapping-9-billion-variants-really-changes\/"},"modified":"2026-10-23T17:27:36","modified_gmt":"2026-10-23T15:27:36","slug":"alphagenome-atlas-what-mapping-9-billion-variants-really-changes","status":"publish","type":"post","link":"https:\/\/aivancity.ai\/blog\/en\/alphagenome-atlas-what-mapping-9-billion-variants-really-changes\/","title":{"rendered":"AlphaGenome Atlas: what mapping 9 billion variants really changes"},"content":{"rendered":"\n
\n

\n L<\/span>aunched by Google DeepMind<\/strong> on\n September 8, 2026<\/strong>, AlphaGenome Atlas<\/strong> makes\n available predictions of the molecular effects of\n nine billion possible single-letter substitutions<\/strong>\n in the human genome. These are neither nine billion mutations\n observed in patients nor a catalog of diagnoses, but rather a\n map computed from the reference genome<\/strong>. The real issue\n is therefore less about celebrating its scale than about understanding\n what this infrastructure makes it possible to\n prioritize, what it does not demonstrate, and under what conditions its\n results can be used responsibly.<\/strong>\n <\/p>\n<\/div>\n\n\n\n

\n\n
\n 01\n <\/div>\n\n

\nWhat Google DeepMind actually released\n <\/h2>\n\n<\/div>\n\n\n\n

AlphaGenome Atlas is a database of predictions precomputed with AlphaGenome, Google DeepMind’s genomics model. For each position in the human reference genome, the team simulated the three possible substitutions of one DNA base for another. This theoretical space yields roughly nine billion single-nucleotide variants, often abbreviated as SNVs. The word \u201catlas\u201d therefore refers to a systematic exploration of possibilities, not a census of variants actually present in the population.[1]<\/a>[2]<\/a><\/sup><\/p>\n\n\n\n

The resource represents about one petabyte of data. Researchers can access it through a web portal that is free for academic use, as well as through a dedicated application programming interface. Google DeepMind also announced an integration with Google Antigravity and plans commercial access through Google Cloud, with no detailed timeline at the time of verification.[1]<\/a>[4]<\/a><\/sup><\/p>\n\n\n\n

The Atlas pairs variants with several molecular-effect predictions and a composite score called AlphaGenome Variant Impact, or AVI. This score combines information from AlphaGenome and AlphaMissense to rank variants in both coding and non-coding regions. A high score signals a priority for review, but on its own it is neither proof of causality nor a diagnosis.[1]<\/a>[2]<\/a><\/sup><\/p>\n\n\n\n

Clinical caution is explicit in Google DeepMind’s documentation. AlphaGenome and the Atlas are neither validated nor approved for clinical use. They must not replace medical advice, regulated genetic testing or experimental validation.[1]<\/a>[4]<\/a><\/sup><\/p>\n\n\n\n

\n\n
\n 02\n <\/div>\n\n

\nWhat is actually new\n <\/h2>\n\n<\/div>\n\n\n\n

The AlphaGenome model did not appear with the Atlas. It had already been described in a Nature paper published in January 2026. That paper presents a model capable of processing up to one million base pairs and predicting thousands of functional signals, including gene expression, RNA splicing, chromatin accessibility, transcription factor binding and certain contacts between regions of the genome.[3]<\/a><\/sup><\/p>\n\n\n\n

The main novelty lies in the change of scale and access. Instead of running a prediction for each variant under study, researchers can query a database in which the effects of every possible substitution have already been computed. This precomputation lowers the initial cost of exploration and makes it easier to compare variants across the entire genome.<\/p>\n\n\n\n

The other contribution is the ambition to connect coding regions, which directly serve to produce proteins, with non-coding regions, which notably play a role in regulation. The latter account for a large share of human variation and remain difficult to interpret. The AVI offers a common measure for prioritizing them, but its scope must be assessed separately from that of the underlying model, as the study devoted to the Atlas was still a preprint as of October 6, 2026.[2][<\/a>3]<\/a><\/sup><\/p>\n\n\n\n

This distinction is essential. The Nature paper provides a peer-reviewed evaluation of the AlphaGenome model. It does not constitute an independent validation of all the Atlas’s functions, the AVI score or every prediction contained in the database.<\/p>\n\n\n\n